← brief for 2026-08-12 · Slowing decline

Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC

Page A Peer reviewed Meta-analysis or large trial

Key takeaways

A large Phase 3 trial tested a drug called atacicept for IgA nephropathy, a common cause of kidney damage. The drug aims to calm the immune signals that drive the disease. The results were published in a major medical journal. A trial this large and carefully run carries real weight for how this disease may be treated.

Source

Page · Forager · 2026-08-13
https://www.nephjc.com/news/atacicept-origin3-gtfb36